Yes i think at least another year will be worth it.
PAB looks like it may be at the start of a longer term trend reversal by looking at the 200 day SMA.
A much safer place to be when the biotech sector is under pressure. A significant drop form here would be more of an oportunity if you still like the fundamentals.
Maybe less than 0.1% of the population would understand the science of SM6 and Im happy for someone to point out why the below statement is not significant. To me it does seem remarkable given the patients in the trial had failed everything else and have low medium survival period of 9 months if i remember correctly. From failure of all available drugs to partial response?
"One patient who received 3mg/kg of PAT-SM6 was stable for 138 days before additional therapy was needed whilst another patient, who received 6mg/kg of PAT-SM6, has been stable for 154 days and is currently therapy free".
After chemotherapy:
"Remarkably, 7/ 11 patients responded very positively with a partial response (PR) while 3 others responded with SD indicating that PAT-SM6 treatment may make cancer cells more sensitive to killing by other chemotherapeutics"
Again id be happy for knowledge on why it is not significant rather than views of hope that it is.
The SP went down on the day the data was released.
lets see if the end of day dump happens today.
PAB Price at posting:
3.5¢ Sentiment: None Disclosure: Held
